Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
NCT04933695
Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
NCT05631249
RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC
NCT05273047
A Study of Sotorasib in People With Non-Small Cell Lung Cancer
NCT06582771
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
NCT05398094
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AMG 510
Administered as an oral tablet.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ineligibility for participation in any Amgen-sponsored ongoing clinical study of the investigational product
* Pathologically documented, locally-advanced and unresectable or metastatic Non Small-Cell Lung Cancer (NSCLC) with KRAS p.G12C mutation confirmed through molecular testing
* Exhausted other standard of care options for locally advanced and unresectable or metastatic NSCLC disease including platinum-based combination chemotherapy and programmed cell death protein 1/programmed death-ligand 1 (PD 1/PD-L1) immunotherapy (unless medically contraindicated)
* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
Exclusion Criteria
* Active brain metastases
* Active hepatitis B or hepatitis C virus
* Current active malignancy other than NSCLC
* Currently or previously enrolled in a prior sotorasib study unless radiographic disease progression confirmed, able to remain on long term follow up of their original protocol and receives medical monitor approval
* Female participants planning to become pregnant while on study through 7 days after the last dose of sotorasib
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clearview Cancer Institute
Huntsville, Alabama, United States
Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States
Ironwood Cancer and Research Center
Chandler, Arizona, United States
Arizona Oncology Associates Professional Corporation
Tucson, Arizona, United States
San Luis Valley Health Regional Medical Center
Alamosa, Colorado, United States
Kaiser Permanente
Lone Tree, Colorado, United States
Sacred Heart Medical Oncology Group
Pensacola, Florida, United States
Cancer Care Specialists of Central Illinois
Decatur, Illinois, United States
McFarland Clinic PC
Ames, Iowa, United States
Des Moines Oncology Research Association
Des Moines, Iowa, United States
Saint Joseph East
Lexington, Kentucky, United States
Louisiana Hematology Oncology Associates
Baton Rouge, Louisiana, United States
Northern Light Cancer Center
Brewer, Maine, United States
University of Pittsburgh Medical Center Western Maryland
Cumberland, Maryland, United States
Maryland Oncology Hematology, PA
Rockville, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Mid Michigan Medical Center
Midland, Michigan, United States
Saint Lukes Cancer Institute
Kansas City, Missouri, United States
Oncology Hematology Associates
Springfield, Missouri, United States
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Englewood Hospital and Medical Center
Englewood, New Jersey, United States
Overlook Medical Center
Summit, New Jersey, United States
Wake Forest Baptist Comprehensive Cancer Research Center
Winston-Salem, North Carolina, United States
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, United States
LeHigh Valley Hospital
Allentown, Pennsylvania, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Scranton Hematology Oncology
Scranton, Pennsylvania, United States
Erlanger East Hospital
Chattanooga, Tennessee, United States
Baptist Cancer Center
Memphis, Tennessee, United States
Saint Marys Medical Center
Huntington, West Virginia, United States
Instituto Médico Especializado Alexander Fleming
Capital Federal, Buenos Aires, Argentina
Hospital Aleman
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Cemic
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Clínica Universitaria Privada Reina Fabiola
Córdoba, , Argentina
Hospital Sirio Libanes
Brasília, Federal District, Brazil
Personal Oncologia de Precisao e Personalizada
Belo Horizonte, Minas Gerais, Brazil
Instituto de Oncologia do Parana
Curitiba, Paraná, Brazil
Liga Norte-Riograndense Contra O Cancer
Natal, Rio Grande do Norte, Brazil
YNOVA Pesquisa Clinica
Florianópolis, Santa Catarina, Brazil
Fundacao Pio 12 Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Oncoclinicas Rio de Janeiro S A
Rio de Janeiro/RJ, , Brazil
Meir Medical Center
Kfar Saba, , Israel
Rabin Medical Center
Petah Tikva, , Israel
Shaare Zedek Medical Center
Petah Tikva, , Israel
King Fahad Specialist Hospital
Dammam, , Saudi Arabia
King Abdulaziz Medical City - National Guard Hospital
Riyadh, , Saudi Arabia
King Saud University Medical City-King Khalid University Hospital
Riyadh, , Saudi Arabia
King Faisal Specialist Hospital
Riyadh, , Saudi Arabia
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, , Taiwan
Chung Shan Medical University Hospital
Taichung, , Taiwan
Veterans General Hospital - Taichung
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Linkou Chang Gung Memorial Hospital
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20190436
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.